Journal of Infectious Diseases and Diagnosis

Biology and Clinical Implications of Occult Hepatitis B Virus Infection: A Contemporary Overview

Chen Bao^* Department of Virology, Wuhan University, Wuhan, China
^*Correspondence: Chen Bao, Department of Virology, Wuhan University, Wuhan, China, Email:

Received: 03-Jul-2023, Manuscript No. JIDD-23-22536; Editor assigned: 05-Jul-2023, Pre QC No. JIDD-23-22536 (PQ); Reviewed: 20-Jul-2023, QC No. JIDD-23-22536; Revised: 27-Jul-2023, Manuscript No. JIDD-23-22536 (R); Published: 03-Aug-2023, DOI: 10.35248/2576-389X.23.08.223

About the Study

Occult Hepatitis B Virus (HBV) infection, characterized by the presence of HBV DNA in the absence of detectable Hepatitis B Surface Antigen (HBsAg), has garnered increasing attention in the realm of viral hepatitis research. In recent years, advancements in molecular techniques and a deeper understanding of the virus-host interactions have led to a renewed focus on unraveling the complex biology and clinical implications of this enigmatic entity [1-3]. This study delves into the significant updates made in the statements regarding the biology and clinical impact of occult HBV infection, shedding light on the evolving landscape of this intriguing phenomenon.

Biology of occult HBV infection

The updated statements reflect the progress made in elucidating the intricate biology of occult HBV infection. Initially considered a mere variant of chronic HBV infection, occult infection is now recognized as a distinct entity with unique virological features [4]. Studies have revealed that occult HBV infection may arise from a spectrum of scenarios, including resolved acute infections, occult co-infections with other hepatitis viruses, and suppression of viral replication by host immune responses. The statements emphasize the importance of understanding these diverse pathways to improve diagnostics, therapeutic interventions, and preventive strategies.

Genetic and molecular insights

Advancements in genetic sequencing technologies have enabled researchers to delve deeper into the genetic diversity of occult HBV strains. The updated statements underscore the significance of deciphering viral genetic variations in occult infection [5,6]. Variability in the pre-S/S region of the HBV genome, deletions in the HBV DNA, and mutations in the X gene have been associated with occult infection. These insights provide valuable clues about viral replication, immune escape mechanisms, and potential oncogenic properties. By acknowledging the genetic heterogeneity of occult HBV, the statements underscore the need for tailored approaches to studying and managing this infection.

Clinical impact and management

The clinical implications of occult HBV infection continue to unfold, prompting revisions in the statements regarding its impact on liver disease progression and management strategies [7]. While earlier studies suggested a relatively benign course, recent evidence challenges this notion. Occult HBV infection has been implicated in liver fibrosis, cirrhosis, and Hepatocellular Carcinoma (HCC) development. The updated statements highlight the importance of vigilance in monitoring occultinfected individuals, particularly those with underlying liver diseases. Additionally, the potential risk of occult HBV transmission through blood products and organ transplantation has prompted the inclusion of stringent screening measures in clinical practice [8].

Diagnostic challenges and advances

Accurate diagnosis of occult HBV infection remains a formidable challenge due to the low viral load and absence of HBsAg. The updated statements emphasize the need for refined diagnostic algorithms that incorporate molecular techniques such as Polymerase Chain Reaction (PCR) and Reverse Transcription PCR (RT-PCR). These methods enable sensitive detection of HBV DNA in various clinical specimens, facilitating early identification of occult infection [9]. The role of liver biopsy and non-invasive fibrosis assessment tools in assessing occultassociated liver disease is also highlighted, underscoring a multidisciplinary approach to diagnosis.

Therapeutic approaches and future directions

In sight of the evolving understanding of occult HBV infection, the statements reflect a shift in therapeutic paradigms. While antiviral therapy was initially considered unnecessary in asymptomatic occult carriers, emerging evidence suggests potential benefits in preventing liver disease progression. The statements advocate for individualized treatment decisions based on factors such as viral load, liver function, and fibrosis stage [10]. Furthermore, the commentary discusses ongoing research into immunomodulatory therapies that aim to boost host immune responses against occult HBV.

Conclusion

The update of statements on the biology and clinical impact of occult HBV infection reflects the dynamic nature of viral hepatitis research. The evolving understanding of occult infection's complex biology, clinical significance, diagnostic challenges, and therapeutic considerations underscores the need for continued collaboration between researchers, clinicians, and policymakers. As the landscape of occult HBV infection continues to unfold, these updated statements provide a comprehensive foundation for guiding future research directions and clinical practices, with the ultimate goal of improving patient outcomes and reducing the global burden of hepatitis Brelated liver disease.

References

1. Polosukhin VV, Richmond BW, Du RH. Secretory IgA deficiency in individual small airways is associated with persistent inflammation and remodeling. Am J Respir Crit Care Med. 2017;195(8):1010-1021.

   [Crossref] [Google Scholar] [PubMed]

2. Lareau SC, Fahy B, Meek P, Wang A. Chronic obstructive pulmonary disease (COPD). Am J Respir Crit Care Med. 2019;199(1):P1-P2.

   [Crossref] [Google Scholar] [PubMed]

3. Wang C, Xu J, Yang L. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH]study): A national cross-sectional study. Lancet 2018;39l(2):1706-1717.

   [Crossref] [Google Scholar] [PubMed]

4. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med. 2006;3(11):e442.

   [Crossref] [Google Scholar] [PubMed]

5. BR Celli, W MacNee. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23(6):932-946.

   [Crossref] [Google Scholar] [PubMed]

6. Cubas-Atienzar AI, Kontogianni K, Edwards T. Limit of detection in different matrices of 19 commercially available rapid antigen tests for the detection of SARS-CoV-2. Sci Rep. 2021;11:18313.

   [Crossref] [Google Scholar] [PubMed]

7. Zhou H, Wang C, Rao J, Chen L, Ma T, Liu D. The impact of sample processing on the rapid antigen detection test for SARS-COV-2: Virus inactivation, VTM selection, and sample preservation. Biosafety and Health. 2021;3(5):238-243.

   [Crossref] [Google Scholar] [PubMed]

8. Toppings NB, Oberding LK, Lin YC, Evans D, Pillai DR. The role of sub genomic RNA in discordant results from reverse transcription-polymerase chain reaction tests for COVID-19. Arch Pathol Lab Med. 2022;146(7):805-813.

   [Crossref] [Google Scholar] [PubMed]

9. Pollock NR, Savage TJ, Wardell H, Lee R, Mathew A, Stengelin M. Correlation of SARS-CoV-2 nucleocapsid antigen and RNA concentrations in nasopharyngeal samples from children and adults using an ultrasensitive and quantitative antigen assay. J Clin Microbiol. 2021;59(4):e03077-e04020.

   [Crossref] [Google Scholar] [PubMed]

10. Kanji JN, Bailey A, Fenton J, Lindsay LR, Dibernardo A, Toledo NPL. Stability of SARS-COV-2 IGG in multiple laboratory conditions and blood sample types. J Clin Virol. 2021;142:104933.

    [Crossref] [Google Scholar] [PubMed]